N/A N=79 Leveraging Technology to Address Unhealthy Drug Use in Primary Care Settings
Addiction
Primary: Receipt of Brief Intervention (BI) for Drug Use at Baseline Visit — 17; 33 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=127 Cocaine Use Reduction and Health
Cocaine Use Disorder
Primary: Endothelin-1 Levels — 2.15; 2.063; 1.956 pg/ml
N/A N=2,272 Drug Use Investigation of Jzoloft.
Panic Disorder · Depression
Primary: Number of Participants of Treatment Related Adverse Events (TRAEs) — 263 participants
N/A N=3,939 Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)
Smoking Cessation
Primary: Risk Factors for the Frequency of Treatment Related Adverse Events - Gender. — 377; 336 participants — p=<0.001
N/A N=250 Survey to Identify Substance Use in Teenagers and Adolescents
Anesthesia
Primary: Number of Participants With Adolescent and Parent Reported Alcohol, Drug, Vaping and Tobacco Usage — 1; 1; 0; 425 Participants
Early Phase 1 N=30 Behavioral Effects of Pregabalin and Cannabis
Cannabis-use Disorders
Primary: Number of Self-administered Puffs of Smoked Cannabis Containing Active THC Concentrations Compared to Placebo Under Controlled Laboratory Conditions — 2.00; 2.67; 3.60…
N/A N=2,695 Screening and Brief Advice to Reduce Teen Substance Use
Substance Related Disorders
Primary: Past-90-day Substance Use at 3 Months Among Baseline Substance Users - New England, USA — 162; 121 Participants — p=< 0.05
Phase 2 N=24 The Effect of Prescription Medications in Marijuana Users
Marijuana Abuse
Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale
N/A N=1,194 Drug Use Investigation Of Gabapentin
Epilepsies, Partial
Primary: Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert — 27 participants
N/A N=1,216 Preventing Drug Abuse Among Sexual Minority Youth
Substance Abuse
Primary: Average Number of Times Youth Drank Alcohol in the Past Month — 0.83; 1.03 number of times
Early Phase 1 N=138 Drugs Brain and Behavior (DDP)
Stimulant Use
Primary: Change in SUbjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 19.2; 57.8…
N/A N=2,057 The Tobacco, Alcohol, Prescription Medication and Other Substances Tool
Substance Use Disorder
Primary: Diagnostic and Statistical Manual-5 (DSM-5) Alcohol Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview…
N/A N=7,740 Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
N/A N=28 Individual Differences in the Response to Drugs
Healthy
Primary: Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration — 4.79; 12.83; 11.08; 12.17 units on a scale
N/A N=230 Drug Use Investigation of Somatropin for GHD-ADULTS.
Dwarfism, Growth Hormone Deficiency
Primary: Number of Participants With Treatment Related Adverse Events. — 29 participants
Phase 2 N=20 The Discriminative Effects of Tramadol in Humans
Opioid Abuse · Opioid Addiction · Stimulant Abuse
Primary: Acquisition of Discrimination Assessed by Accuracy of the Discrimination Test — 87; 87.5; 90 percent of correct response
N/A N=51 Marijuana Use, Strength Training, and Alcohol Consumption (MUSTAC) Study
Chronic Pain
Primary: Alcohol Demand: Breakpoint — -6.00; -2.07; -1.81; -1.09 dollars/drink — p=.26
Early Phase 1 N=25 Imaging the Neurochemistry of Drug Addiction With PET
Smoking · Cannabis
Primary: Change in Dopamine Levels at Baseline and After Drug of Dependence Administration as Confirmed by PET Images. — 0.0388; 0.033; 0.0285; 0.0368 mm^3
Phase 2 N=23 Caffeine and Cocaine
Cocaine Dependence
Primary: Visual Analog Scale Subjective Rating of Drug Effects — 8.65; 9.85; 13.65; 10.43 units on a scale
N/A N=202 Randomized Controlled Trial of eScreen for Problematic Drug Use
Problematic AOD Use
Primary: Drug Use Disorders Identification Test-Consumption (DUDIT-C) — 4.8; 4.5 units on a scale
N/A N=1,408 Drug Use Investigation Of Effexor (SECONDARY DATA COLLECTION STUDY; SAFETY AND EFFICACY OF EFFEXOR.UNDER JAPANESE MEDICAL PRACTICE)
Depression/Depressed State
Primary: Number of Participants With Adverse Drug Reactions — 312; 4 Participants
Phase 2 N=107 Interactive Motivational Media for Perinatal Drug Abuse - 3
Substance-Related Disorders
Primary: Number of Participants With Drug Use at 3 Months — 49; 48 participants
Phase 1 N=8 Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
N/A N=150 Intensive Models of HCV Care for Injection Drug Users
Hepatitis C · Medication Adherence
Primary: Electronically Monitored Medication Adherence — 86; 80; 75 Percentage of medication taken
N/A N=240 HealthCall:Brief Intervention to Reduce Non-injecting Drug Use in HIV Primary Care Clinics
Mental and Behavioral Disorders Due to Harmful Drug Use
Primary: Total Number of Days of Primary Drug Used in the Prior 30 Days — 5.07; 3.61; 4.73 Days
Early Phase 1 N=18 Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer
Active Cocaine Users
Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 0.06; 0.94; 0.75; 0.88 cocaine choices
N/A N=122 An App to Reduce Cannabis Use Among Emerging Adults
Cannabis Use
Primary: App Feasibility — 122 Participants
Phase 1 N=19 Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)
Alcohol Use Disorder
Primary: Reinforcing Effects (Pre-Alcohol Dose Consumption) — 0.005; .01; 0.007; 0.005 Units on a Theoretical Scale
N/A N=2,492 Drug Use Investigation for Toviaz
Overactive Bladder (OAB)
Primary: Number of Participants With Treatment-Related Adverse Events — 415 Participants
Early Phase 1 N=9 Impact of a Non-Drug Choice on Cocaine Reinforcement
Cocaine Dependence
Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 2.75; 1.38; 1.38; 4.75 cocaine choices